ALFA Finder| Management target | Revenue 17.5% |
|---|
| Revenue growth | 3.93% YoY for Q1 FY27. |
|---|---|
| Margins | EBITDA margin improved to 9.99% from 7.34% YoY. |
| Demand visibility | Strong regulated market pipeline; USFDA/EU GMP clearances secured. |
| Management confidence | High; citing confident opening note for FY27. |
Growth
Revenue reached ₹193.81 Cr; EBITDA rose 41.56% YoY to ₹19.36 Cr; PAT surged 37.63% YoY to ₹11.42 Cr.
Outlook
Management anticipates 15-20% per annum steady growth; four new products under development including Vonoprazon Fumarate and Edoxaban Tosylate.
Risks
Currency risk cited; management is diversifying export markets to mitigate impact. Competitive intensity in generic APIs remains.
Investor Presentation filed with BSE, NSE: ANUHPHR. Summary written with AI assistance from the document.
Anuh Pharma Ltd: key numbers
- Share price
- ₹83.30
- Market cap
- ₹834.9 Cr
- Revenue (annual)
- ₹771.7 Cr
- Net profit (annual)
- ₹41.05 Cr
- P/E (TTM)
- 17.5×Sector 43.8×
- Promoter holding
- 71.80%+0.00% QoQ
- FII holding
- 0.11%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Anuh Pharma Ltd
All →Anuh Pharma Promoter Reclassification
Anuh Pharma's promoter group member Nina Vijay Shah withdrew her request to reclassify to the public category. She remains in the promoter group.
Anuh Pharma Q2 FY27 Results: Net Profit ₹11.2 Cr, Up 47.4% YoY
Anuh Pharma Ltd reported revenue from operations of ₹185.2 Cr (-0.4% YoY) and net profit of ₹11.2 Cr (+47.4% YoY) for Q2 FY27.
- Key figure
- Net profit ₹11.2 Cr · +47.4% YoY
Anuh Pharma Board Meeting Date
Anuh Pharma's board meets on 30 October 2026 to approve Q1/H1 FY27 results. Trading window closed for insiders until 1 November 2026.
Anuh Pharma Acquisition Worth ₹72.9 Cr
Anuh Pharma signed an Asset Transfer Agreement to acquire a manufacturing facility from Vanquest Pharma for ₹72.90 Crore, increasing its production capacity by 525 MTPA.
- Value
- ₹72.90 Cr
- manufacturing capacity
- 525.0 MTPA
Anuh Pharma Debt & Borrowing: ₹75 Cr
Anuh Pharma Ltd board approved a loan of ₹75 Crore to finance manufacturing asset investments for expanding production capacity.
- Value
- ₹75.00 Cr
Anuh Pharma Other Announcement
Anuh Pharma Ltd filed the quarterly compliance certificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018, as issued by its RTA.